Semaglutide is not close to being an approved cocaine-use-disorder medication, but a 2026 rat study gives the idea a more demanding preclinical test than ordinary self-administration experiments. After 5 days of treatment, rats shifted away from cocaine choice without losing total operant responding, which separates the result from a broad appetite-suppression artifact. Research Highlights Semaglutide …
A 2026 case series of 10 adults with refractory postherpetic neuralgia found: 3 of 8 patients responded to a spinal cord stimulation trial, 2 kept meaningful 24-month relief after implantation, and 3 dorsal root entry zone lesioning cases reported 60-90% pain relief at 24 months.1 The data are too small to rank the procedures, but …
A 2026 iScience study found that adults could learn a new auditory cue to visual depth after about 1 hour, but full perceptual integration did not appear reliably at the group level: only 31 of 63 participants, or 49%, gained precision when the novel cue was combined with familiar visual disparity.1 The sharp interpretation separates …
A 2026 cerebrospinal-fluid proteomics preprint involving 87 amyotrophic lateral sclerosis (ALS) patients, 89 healthy controls, and 61 neurological controls reported 399 ALS candidate proteins, complement markers that tracked disease stage, and a 5-protein panel that classified ALS vs. healthy controls with ROC AUC 0.95 after the best-known neurodegeneration markers were removed.1 Research Highlights CSF proteomics …
A 2026 case-control study found that treatment-naive adults with attention-deficit/hyperactivity disorder (ADHD) had much lower serum SIRT-1, Nrf-2, and HO-1 than matched controls, while TNF-α did not differ. The pattern points more toward impaired antioxidant-defense regulation than a simple broad-inflammation story. Research Highlights Antioxidant-defense markers were lower: adults with ADHD had lower SIRT-1 (9.36 vs. …
A 2026 whole-genome sequencing preprint found rare variant signals in 2 multiplex obsessive-compulsive disorder (OCD) families: an NPY5R missense variant in 10 of 15 affected people in 1 pedigree, plus DLGAP1 and MAPK8IP3 signals that tracked all 3 sequenced cases in a branch of a second pedigree.1 The finding is a candidate-gene result, not a …
A 2026 PRO-ACT analysis of amyotrophic lateral sclerosis (ALS) trial data found a signal that ordinary ALSFRS total-score slopes cannot even express: Shannon entropy trajectories diverged between pooled active and placebo arms, including a 5-month delay in peak Fine Motor distributional spread for active-arm patients.1 Research Highlights Entropy found an endpoint-level signal: Rodriguez analyzed 7,512 …